Abstract:OBJECTIVE To investigate the clinical features and prognosis of pulmonary arterial hypertension (PAH) secondary to connective tissue disease (CTD). METHODS Eighty-two patients diagnosed as having CTD associated PAH (CTDaPAH) were retrospectively analyzed among 2189 patients with CTD in Peking Union Medical College Hospital between January 1997 and September 2004. RESULTS Eighty-two (3.7%) patients (75 females and 7 males), aged 41 years, were found to have CTDaPAH. The underlying diseases included mixed CTD (MCTD), systemic scleroderma, primary Sjogren's syndrome (pSS), systemic lupus erythematosus (SLE), undifferentiated CTD, dermatomyositis and Behcet disease. PAH was an earlier complication in patients with SLE or MCTD (median onset, 3 and 2 years, respectively), compared to those with pSS (6 years). The most common clinical manifestations of CTDaPAH were dyspnea on exertion (84.1%) and Raynaud's phenomenon (56.1%). The mean pulmonary artery systolic pressure (PASP) level of these patients was (65.71 +/- 20.44) mm Hg, with the decrease of PaO2 and PaCO2 level [(70.37 +/- 15.02) mm Hg, (27.88 +/- 6.46) mm Hg, respectively]. The diffusing capacity of the lungs measured using carbon monoxide was decreased [D(L)CO pred% (51 +/- 14)%]. 13%, 32%, 29% and 8% of these patients were grouped to class I, II, III and IV, respectively, on NYHA functional classification. Although the patients received treatment for underlying CTD and traditional vasodilators, the condition of elevated PASP had not been improved with the exception of a marginal decrease of PASP in SLE patients [(76.47 +/- 18.20) mm Hg --> (69.08 +/- 20.77) mm Hg]. Thirteen (15.85%) patients died during an average of 4.33 years follow-up, compared to the mortality of those with non-CTDaPAH (2.75%, P < 0.01). Lower level of PaO2 [(58.51 +/- 16.16) mm Hg] and higher proportion of NYHA class III, IV [38.46% (5/13), 30.77% (4/13), respectively] were observed in death group compared to survivors [PaO2 (73.25 +/- 14.32) mm Hg; NYHA class III, IV 34.78% (24/69), 5.80% (4/69), respectively] (P < 0.01; P < 0.05; respectively). CONCLUSIONS PAH is a common complication of CTDs, which occurs often in the forth year after initial CTD manifestations and is earlier in patients with SLE or MCTD, compared to those with pSS. The most common manifestations of CTDaPAH are dyspnea on exertion and Raynaud's phenomenon. CTDaPAH could be very severe, which will lead to lower level of PaO2 and more advanced NYHA classification, and therefore reduce the survival rate of the patients. Doppler echocardiography and lung function test are necessary to detect PAH early.

Early detection and treatment of connective tissue disease associated pulmonary arterial hypertension

The treatment strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving into the future

Endothelial Progenitor Cell-Based Therapy for Pulmonary Arterial Hypertension

Connective tissue disease‐associated pulmonary hypertension: A comprehensive review

Recent Advances in the Treatment of Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases

The Clinical Analysis of Pulmonary Arterial Hypertension in Connective Tissue Disease

Targeted treatment strategy for patients with severe pulmonary hypertension secondary to connective tissue diseases

Serum Biomarkers in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension

10-Year Survival of Pulmonary Arterial Hypertension Associated with Connective Tissue Disease: Insights from a Multicentre PAH Registry

The role of immune cells in the pathogenesis of connective tissue diseases-associated pulmonary arterial hypertension

Treatment of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review and meta-analysis

Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: A COMPERA analysis

Characteristics Of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: A Retrospective Cohort Study

Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study

Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients.

Clinical Analysis Connective Tissue Disease Related Pulmonary Arterial Hypertension

The Role of Pulmonary Function Test for Pulmonary Arterial Hypertension in Patients with Connective Tissue Disease

Therapeutic Monitoring Response of Pulmonary Arterial Hypertension Using a Combined Computed Tomography- Computational Fluid Analysis Strategy.

Pulmonary hypertension in connective tissue diseases: What every CTD specialist should know - but is afraid to ask!

Pharmacological management of connective tissue disease-associated pulmonary arterial hypertension

2023 Taiwan Society of Cardiology (TSOC) and Taiwan College of Rheumatology (TCR) Joint Consensus on Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.